KMDA
Kamada Ltd
NASDAQ · Biotechnology
$8.21
+0.19 (+2.37%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 160.07M | 138.21M | 66.34M | 67.17M | 56.23M |
| Net Income | 13.92M | 10.82M | -1,785,693 | -1,989,318 | -1,893,818 |
| EPS | — | — | — | — | — |
| Profit Margin | 8.7% | 8.3% | -2.7% | -3.0% | -3.4% |
| Rev Growth | +15.8% | +15.8% | +6.0% | +14.3% | -2.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 9.65M | 9.65M | 40.73M | 36.09M | 37.79M |
| Total Equity | 227.13M | 227.13M | 361.61M | 407.35M | 369.18M |
| D/E Ratio | 0.04 | 0.04 | 0.11 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 13.42M | 11.01M | -2,514,054 | -2,803,887 | -1,985,807 |
| Free Cash Flow | — | — | -2,843,002 | -2,727,774 | -1,789,276 |